Ambrx Biopharma Cayman, Inc.

Ambrx Biopharma Cayman, Inc. (AMAM) priced its initial public offering on Jun 21, 2021 at $18.00 per ADS, raising $126M, and listed on NYSE. At the IPO price its market capitalization was about $4.75B. Goldman Sachs was lead-left underwriter, joined by BofA Securities and TD Cowen. Cooley and Maples and Calder advised the company and Goodwin Procter, Allbright Law Offices and JunHe advised the underwriters.

Ambrx Biopharma Cayman, Inc. is a clinical-stage biologics company developing engineered precision biologics. Its expanded genetic code platform inserts synthetic amino acids into proteins, enabling candidates such as antibody-drug conjugates, bispecific antibodies and modified cytokines.

Status

IPO

Ticker

AMAM

Exchange

NYSE

Priced

Jun 21, 2021

IPO price

$18.00 per ADS

Raised

$126M

Market cap at IPO price

$4.75B

First filed

May 28, 2021

Underwriters

Goldman Sachs, BofA Securities and TD Cowen

Company counsel

Cooley and Maples and Calder

Underwriters' counsel

Goodwin Procter, Allbright Law Offices and JunHe

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.